Patch Testing With a New Composition of the Mercapto Mix-A Multicenter Study from the International Contact Dermatitis Research Group.


Journal

Dermatitis : contact, atopic, occupational, drug
ISSN: 2162-5220
Titre abrégé: Dermatitis
Pays: United States
ID NLM: 101207335

Informations de publication

Date de publication:
Historique:
pubmed: 7 1 2021
medline: 16 11 2021
entrez: 6 1 2021
Statut: ppublish

Résumé

Mercaptobenzothiazole compounds are associated with allergic contact dermatitis caused by rubber products. Several screening substances have been used for patch testing. To compare the frequency of positive test reactions to a mercapto mix containing a higher concentration of 2-mercaptobenzothiazole with reactions to the combination of 2-mercaptobenzothiazole 2.0% and mercapto mix 2.0%. There were 7103 dermatitis patients in 12 International Contact Dermatitis Research Group dermatology departments who were patch tested with 2-mercaptobenzothiazole 2.0% petrolatum (pet.), mercapto mix 2.0% pet., and mercapto mix 3.5% pet. Contact allergy to the 3 test preparations varied among the 12 centers: 2-mercaptobenzothiazole 2.0% pet. (0-2.4%), mercapto mix 2.0% pet. (0-4.9%), and mercapto mix 3.5% pet. (0-1.4%). 2-Mercaptobenzothiazole 2.0% and mercapto mix 2.0% detected a few more positive patients compared with mercapto mix 3.5%, but the difference was statistically insignificant (mercapto mix 2.0% pet., P = 1.0; 2-mercapto-benzothiazole 2.0% pet., P = 0.66). Mercapto mix 3.5% pet. is not better than 2-mercaptobenzothiazole 2.0% and mercapto mix 2.0% by a difference that is significant. By using only 1 test preparation (mercapto mix 3.5%), an additional hapten could be tested. No cases of suspected/proven patch test sensitization were registered.

Sections du résumé

BACKGROUND BACKGROUND
Mercaptobenzothiazole compounds are associated with allergic contact dermatitis caused by rubber products. Several screening substances have been used for patch testing.
OBJECTIVE OBJECTIVE
To compare the frequency of positive test reactions to a mercapto mix containing a higher concentration of 2-mercaptobenzothiazole with reactions to the combination of 2-mercaptobenzothiazole 2.0% and mercapto mix 2.0%.
METHODS METHODS
There were 7103 dermatitis patients in 12 International Contact Dermatitis Research Group dermatology departments who were patch tested with 2-mercaptobenzothiazole 2.0% petrolatum (pet.), mercapto mix 2.0% pet., and mercapto mix 3.5% pet.
RESULTS RESULTS
Contact allergy to the 3 test preparations varied among the 12 centers: 2-mercaptobenzothiazole 2.0% pet. (0-2.4%), mercapto mix 2.0% pet. (0-4.9%), and mercapto mix 3.5% pet. (0-1.4%). 2-Mercaptobenzothiazole 2.0% and mercapto mix 2.0% detected a few more positive patients compared with mercapto mix 3.5%, but the difference was statistically insignificant (mercapto mix 2.0% pet., P = 1.0; 2-mercapto-benzothiazole 2.0% pet., P = 0.66).
CONCLUSIONS CONCLUSIONS
Mercapto mix 3.5% pet. is not better than 2-mercaptobenzothiazole 2.0% and mercapto mix 2.0% by a difference that is significant. By using only 1 test preparation (mercapto mix 3.5%), an additional hapten could be tested. No cases of suspected/proven patch test sensitization were registered.

Identifiants

pubmed: 33405485
doi: 10.1097/DER.0000000000000669
pii: 01206501-900000000-99519
doi:

Substances chimiques

Allergens 0
Benzothiazoles 0
captax 5RLR54Z22K
Petrolatum 8009-03-8
Rubber 9006-04-6

Types de publication

Comparative Study Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

160-163

Informations de copyright

Copyright © 2021 American Contact Dermatitis Society. All Rights Reserved.

Déclaration de conflit d'intérêts

The authors have no funding or conflicts of interest to declare.

Références

ICDRG. Patch test allergens [editorial]. Contact Dermatitis Newsletter. 1968; 38.
ICDRG. Patch test allergens [editorial]. Contact Dermatitis Newsletter. 1969; 82–84.
Diepgen TL, Bruynzeel DP, Andersen KE, et al. Mercaptobenzothiazole or the mercapto-mix: which should be in the standard series?Contact Dermatitis 2006;55:36–38.
Hansson C, Agrup G. Stability of the mercaptobenzothiazole compounds. Contact Dermatitis 1993;28:29–34.
Warshaw EM, Raju SI, Mathias CG, et al. Concomitant patch test reactions to mercapto mix and mercaptobenzothiazole: retrospective analysis from the North American Contact Dermatitis Group, 1994–2008. Dermatitis 2013;24:321–327.
Lachapelle J-M, Maibach HI. Patch Testing and Prick Testing A Practical Guide Official Publication of ICDRG. Berlin, Germany: Springer-Verlag; 2003, p78.
Alikhan A, Cheng LS, Ale I, et al. Revised minimal baseline series of the International Contact Dermatitis Research Group: evidence-based approach. Dermatitis 2011;22:121–122.
Bruze M, Isaksson M, Gruvberger B, et al. Recommendation of appropriate amounts of petrolatum preparation to be applied at patch testing. Contact Dermatitis 2007;56:281–285.
Fregert S. Manual of Contact Dermatitis. 2nd ed. Copenhagen, Denmark: Munksgaard; 1981.
Engfeldt M, Isaksson M, Glas B, et al. Patch testing with a new composition of mercapto mix: a multi-centre study by the Swedish Contact Dermatitis Research Group. Acta Derm Venereol 2019;99:960–963.
Bruze M. Thoughts on how to improve the quality of multicentre patch test studies. Contact Dermatitis 2016;74:168–174.
Bruze M, Condé-Salazar L, Goossens A, et al. Thoughts on sensitizers in a standard patch test series. The European Society of Contact Dermatitis. Contact Dermatitis 1999;41:241–250.
Isaksson M, Ale I, Andersen KE, et al. Revised baseline series of the International Contact Dermatitis Research Group. Dermatitis 2020;31:e5–e7.

Auteurs

Marléne Isaksson (M)

From the Department of Occupational Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden.

Klaus E Andersen (KE)

Department of Dermatology and Allergy Centre, Odense University Hospital, University of Southern Denmark.

Alicia Cannavó (A)

Clinicas Hospital, Dermatology Department Buenos Aires, Argentina.

Peter Elsner (P)

Department of Dermatology, University Clinic Jena, Germany.

Chee-Leok Goh (CL)

National Skin Centre, Singapore.

Margarida Gonçalo (M)

Department of Dermatology, University Hospital and Faculty of Medicine, University of Coimbra, Portugal.

An Goossens (A)

University Hospital KU Leuven, Dermatology, Belgium.

Suzana Ljubojevic Hadzavdic (SL)

Department of Dermatology and Venereology, University Hospital Center Zagreb, University of Zagreb School of Medicine, Croatia.

Melanie Pratt (M)

University of Ottawa, The Ottawa Hospital, Ottawa, Canada.

Pailin Puangpet (P)

Institute of Dermatology, Bangkok, Thailand.

Denis Sasseville (D)

Division of Dermatology, McGill University Health Centre, Montreal General Hospital, Ottawa, Canada.

Kaushal Verma (K)

Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.

Magnus Bruze (M)

From the Department of Occupational Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH